Select all docs (Max 200)
Narrow Results:
Publication Year
Medical Subject
- Adenosine Deaminase 1
- Adolescent 2
- Adult 1
- Adverse Drug Reaction Reporting Systems 1
- Aged 1
- Aged, 80 and over 1
- Anaphylaxis 1
- Animals 1
- Antibodies, Viral 1
- Antigens, Viral/Analysis 1
- APOBEC Deaminases 1
- Biopsy 1
- Cell Line 1
- Child 2
- Chlorocebus aethiops 1
- Community Health Services 1
- CoronaVirus Infections 2
- CoronaVirus Infections/Diagnosis 1
- COVID-19 2
- COVID-19 / Prevention & Control 1
- COVID-19 Serological Testing 1
- COVID-19 Testing 1
- COVID-19 Vaccines 1
- COVID-19 Vaccines/Administration & Dosage 1
- Diagnostic Tests, Routine 1
- Emergencies 1
- Female 1
- Full Report 1
- Genome, Viral 1
- Granuloma 1
- Humans 2
- Immunization 1
- Immunoglobulin M 1
- Male 1
- Measles-Mumps-Rubella Vaccine 1
- Middle Aged 1
- Primary Immunodeficiency Diseases 1
- RNA-Binding Proteins 1
- Rubella virus 1
- SARS-CoV-2 1
- Sensitivity and Specificity 1
- Skin 1
- Time Factors 1
- Vero Cells 1
- Viral Envelope Proteins 1
- Virus Shedding 1
- Young Adult 1
Personal Author
Corporate Author
Place as Subject
- Arizona 3
Resource Type General
Select all docs (Max 200)
1 -
4 of 4 Results
SELECT A RANGE
SELECT A FORMAT
Refine Results
Refine Results:
- Adenosine Deaminase (1)
- Adolescent (2)
- Adult (1)
- Adverse Drug Reaction Reporting Systems (1)
- Aged (1)
- Aged, 80 and over (1)
- Anaphylaxis (1)
- Animals (1)
- Antibodies, Viral (1)
- Antigens, Viral/Analysis (1)
- APOBEC Deaminases (1)
- Biopsy (1)
- Cell Line (1)
- Child (2)
- Chlorocebus aethiops (1)
- Community Health Services (1)
- CoronaVirus Infections (2)
- CoronaVirus Infections/Diagnosis (1)
- COVID-19 (2)
- COVID-19 / Prevention & Control (1)
- COVID-19 Serological Testing (1)
- COVID-19 Testing (1)
- COVID-19 Vaccines (1)
- COVID-19 Vaccines/Administration & Dosage (1)
- Diagnostic Tests, Routine (1)
- Emergencies (1)
- Female (1)
- Full Report (1)
- Genome, Viral (1)
- Granuloma (1)
- Humans (2)
- Immunization (1)
- Immunoglobulin M (1)
- Male (1)
- Measles-Mumps-Rubella Vaccine (1)
- Middle Aged (1)
- Primary Immunodeficiency Diseases (1)
- RNA-Binding Proteins (1)
- Rubella virus (1)
- SARS-CoV-2 (1)
- Sensitivity and Specificity (1)
- Skin (1)
- Time Factors (1)
- Vero Cells (1)
- Viral Envelope Proteins (1)
- Virus Shedding (1)
- Young Adult (1)
- :Perelygina, Ludmila ;Chen, Min-hsinOctober 28 2019 | PLoS Pathog. 15(10):Rubella viruses (RV) have been found in an association with granulomas in children with primary immune deficiencies (PID). Here, we report the recover...
- :Prince-Guerra, Jessica L. ;Almendares, OliviaJanuary 22 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):Rapid antigen tests, such as the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW), offer results more rapidly (approximately 15-30 minutes) and at a lower ...
- :Prince-Guerra, Jessica L. ;Almendares, OliviaJanuary 19, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? The BinaxNOW rapid antigen test received Emergency Use Authorization by the Food and Drug Administration for t...
- :Prince-Guerra, Jessica L. ;Almendares, OliviaJanuary 22, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR):What is already known about this topic? Anaphylaxis is a severe, life-threatening allergic reaction that occurs rarely after vaccination.What is added...
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.